



## **Intercell AG wins the Scrip Award for Biotech Company of the Year**

**Vienna (Austria), December 11, 2008** – Intercell AG (VSE: ICLL) announced today that the Company has been awarded the Scrip Award for Biotech Company of the Year at last night's ceremony at the London Hilton, Park Lane.

The Scrip Awards are voted for by a panel of esteemed judges from the pharmaceutical industry worldwide. The judging criteria included the Company's pipeline, fund raising and cash position, licensing and partnership deals, and technology.

Vaccine developer Intercell was awarded this prize in recognition of its achievements in 2008 which include the acquisition of Iomai Corporation, reaching its first profitable full year, the alliance with Novartis as well as Intercell's prophylactic Japanese Encephalitis vaccine making significant progress towards its market approval.

CEO of Intercell, Gerd Zettlmeissl, said: "We are delighted to be awarded the title of Biotech Company of the Year in recognition of our hard work and progress. This has been a great year for Intercell in many aspects and we are very positive looking towards 2009."

### **About Intercell AG**

Intercell AG is a growing biotechnology company which focuses on the design and development of novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical need. The Company develops antigens and adjuvants which are derived from its proprietary technology platforms and has in-house GMP manufacturing capabilities. Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Merck & Co., Inc., Wyeth, Sanofi Pasteur, Kyowa Hakko Kirin, and the Statens Serum Institut.

The Company's leading product, a prophylactic vaccine against Japanese Encephalitis, is currently in the process of marketing approval in the US, Europe, Australia and Canada. Marketing approval in the US, Europe and Australia is expected for 2008.

The company's broad development pipeline includes a Travelers' Diarrhea vaccine (patch) in Phase II (start of Phase III expected in 2009), a Pseudomonas vaccine in Phase II, as well as an pandemic Influenza Vaccine Enhancement patch, a partnered S. aureus vaccine in Phase II and four products focused on infectious diseases in preclinical development.

Intercell is listed on the Vienna stock exchange under the symbol "ICLL".

For more information please visit: [www.intercell.com](http://www.intercell.com)





## **Contact Intercell AG**

### **Intercell AG**

Lucia Malfent

Head of Corporate Communications

Campus Vienna Biocenter 3, A-1030 Vienna

P: +43-1-20620-1303

Mail to: [LMalfent@intercell.com](mailto:LMalfent@intercell.com)

*This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.*